BBHC
TVRD

Brown Brothers Harriman & Co’s Tvardi Therapeutics TVRD Stock Holding History

Brown Brothers Harriman & Co’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-86
Closed -$38K – 1161
2017
Q4 		$38K Buy
+86
New +$39.2K ﹤0.01% 549

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Brown Brothers Harriman & Co's TVRD Position: Q1 2018 in Review

Brown Brothers Harriman & Co sold out of Tvardi Therapeutics (TVRD) in Q1 2018, closing a stake of 86 shares — an estimated $38K sold.

Brown Brothers Harriman & Co first reported a position in TVRD in Q4 2017 and held it in 1 quarter. The position peaked at $38K in Q4 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q1 2018.

  • Brown Brothers Harriman & Co reported no remaining Tvardi Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 86 Tvardi Therapeutics shares in Q1 2018, an estimated $38K.
  • Brown Brothers Harriman & Co first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Tvardi Therapeutics position peaked at $38K in Q4 2017.
  • 121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2018, filed 14 May 2018.